Valuation Highnoon Laboratories Limited

Stocks

End-of-day quote Pakistan S.E. 2026-09-11			5-day change	1st Jan Change
924.60 ^PKR	+1.50%		-1.34%	-9.57%

Aug. 27	Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
May. 18	Highnoon Laboratories Appoints Dr. Shahzad Khan as Managing Director of Highnoon Life Sciences	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2024	2025	2026	2027	2028
Market Cap ¹	48,650	54,175	49,169	-	-
Change	-	11.36%	-9.24%	-	-
Enterprise Value (EV)	48,650	54,175	49,169	49,169	49,169
Change	-	11.36%	-9.24%	0%	0%
P/E	14.4x	-	-	-	-
PBR	-	-	-	-	-
PEG	-	-	-	-	-
Capitalization / Revenue	-	1.96x	1.62x	1.44x	1.28x
EV / Revenue	-	0x	1.62x	1.44x	1.28x
EV / EBITDA	-	-	-	-	-
EV / EBIT	-	-	-	-	-
EV / FCF	-	-	-	-	-
FCF Yield	-	-	-	-	-
Dividend per Share ²	-	50	45	52	60
Rate of return	-	4.89%	4.87%	5.62%	6.49%
EPS ²	63.95	-	-	-	-
Distribution rate	-	-	-	-	-
Net sales ¹	-	27,706	30,398	34,163	38,399
EBITDA	-	-	-	-	-
EBIT	-	-	-	-	-
Net income	3,389	-	-	-	-
Net Debt	-	-	-	-	-
Reference price ²	918.22	1,022.49	924.60	924.60	924.60
Nbr of stocks (in thousands)	52,983	52,983	52,983	-	-
Announcement Date	3/26/25	4/7/26	-	-	-

¹PKR in Million²PKR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
HIGHNOON LABORATORIES LIMITED	-	-	-	4.94%	174M
ELI LILLY AND COMPANY	31.96x	11.62x	23.56x	0.62%	1,001B
JOHNSON & JOHNSON	29.63x	-	-	2.02%	642B
ABBVIE INC.	32.65x	7.56x	15.72x	2.69%	451B
ROCHE HOLDING AG	18.78x	4.58x	11.35x	2.9%	340B
NOVARTIS AG	19.52x	5.11x	12.66x	3.19%	263B
ASTRAZENECA PLC	20.44x	4.2x	12.01x	2.1%	247B
AMGEN INC.	24.19x	6.38x	11.35x	2.64%	207B
NOVO NORDISK A/S	12.74x	4.63x	9.67x	3.94%	197B
GILEAD SCIENCES, INC.	-43.8x	6.4x	24.98x	2.27%	180B
Average	16.23x	6.31x	15.16x	2.73%	352.65B
Weighted average by Cap.	23.23x	7.75x	17.18x	2.04%